BioScrip Inc (BIOS) Receives $3.83 Consensus PT from Analysts

BioScrip Inc (NASDAQ:BIOS) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $3.83.

Several research firms have issued reports on BIOS. Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Friday, January 26th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $3.00 target price on shares of BioScrip in a research report on Friday, November 3rd.

BioScrip (NASDAQ:BIOS) remained flat at $$2.93 on Friday. 395,100 shares of the company’s stock were exchanged, compared to its average volume of 887,558. The company has a debt-to-equity ratio of -6.11, a current ratio of 1.91 and a quick ratio of 1.60. The firm has a market capitalization of $373.62, a PE ratio of -4.31 and a beta of 0.19. BioScrip has a 52 week low of $1.35 and a 52 week high of $3.39.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of BioScrip by 1.0% in the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after buying an additional 1,100 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of BioScrip by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after buying an additional 2,622 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of BioScrip by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after buying an additional 8,914 shares during the last quarter. Voya Investment Management LLC raised its position in shares of BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after buying an additional 14,867 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in shares of BioScrip by 10.2% in the second quarter. Teachers Advisors LLC now owns 219,040 shares of the company’s stock valued at $595,000 after buying an additional 20,290 shares during the last quarter. Institutional investors and hedge funds own 85.51% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2018/02/20/bioscrip-inc-bios-receives-3-83-consensus-pt-from-analysts.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply